ClinicalTrials.gg
Not yet recruitingNCT06531291Updated Jul 31, 2024

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

A Phase 2 interventional study of Surufatinib and Serplulimab in ESCC, Biliary Tract Cancer and Gastric Cancer, sponsored by RenJi Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-31.

Sponsored by RenJi Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Biliary Tract Neoplasms with a site in China — 94 open to participants now, 112 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Planned enrollment
65th of 158
80 · median 61
Started
2024
with 23 others
Phase 2
95 of 177
53 open now
Primary completion
2027-08
later than 66 of 111 live
Registered
106th of 177
by date

Among the 177 studies in Biliary Tract Neoplasms with a site in China, this one is the 65th largest by planned enrollment of the 158 interventional ones that give a count, is one of 24 that started in 2024, is one of 95 in phase 2, reaches primary completion later than 66 of the 111 other live ones, and was the 106th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

94 of the 177 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

Currently, there are no standard treatment and relevant exploration for solid tumors patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment ofadvanced solid tumors with NED, in order to provide a new treatment option for advanced solid tumors patients with NED.

Read the detailed description

This is a single-arm, multi-cohort, open-label, single-center, prospective, exploratory clinical study. We planned to enroll 80 patients who would receive surufatinib plus tislelizumab until disease progression, intolerance, or withdrawal of consent. The study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment of advanced solid tumors with NED, in order to provide a new treatment option for advanced solid tumors patients with NED.

03

Conditions studied

  • ESCC
  • Biliary Tract Cancer
  • Gastric Cancer
  • Pancreas Cancer

Keywords

  • surufatinib
  • Neuroendocrine Differentiation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically confirmed locally advanced or unresectable ESCC, BTC, PC or GC with an abnormal NED or NE phenotype (without neuroendocrine morphologic features and positive immunohistochemical expression of at least one neuroendocrine marker (CgA, Syn));
  • Have at least one according to v1.1;
  • performance status: 0-1;
  • No previous systemic therapy;
  • Urine protein\< ++ . If Urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g;
  • Expected survival time > 3 months;

Exclusion criteria

Exclusion Criteria:

  • Have uncontrolled hypertension, defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mm Hg, while under anti-hypertension treatment;
  • With active bleeding or bleeding tendency;
  • Severe history of cardiovascular and cerebrovascular diseases;
  • Other diagnosed within the previous 5 years, except basal cell carcinoma or cervical carcinoma in situ after radical resection.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Surufatinib + serplulimab + standard chemotherapy

    Drug: Surufatinib · Drug: Serplulimab · Drug: standard chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    time from first-dose to the first documented disease progression or death

    Time frame: approximately 1 years

Secondary outcomes

  1. Objective response rate (ORR)

    the proportion of patients with complete response or partial response, using RESIST v1.1

    Time frame: approximately 1 years

  2. Disease Control Rate (DCR)

    the proportion of patients with complete response, partial response or stable disease, using RESIST v1.1

    Time frame: approximately 1 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Aug 2027, 35 months later.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 35 months is below that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2024
First posted
Jul 31, 2024
StartEst.
Aug 10, 2024
Primary completionEst.
Aug 9, 2027
CompletionEst.
Aug 9, 2027
Last update
Jul 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06531291
Lead sponsor
RenJi Hospital
Responsible party
liwei wang (Director of department of oncology, RenJi Hospital) — Principal investigator
First posted
Jul 31, 2024
Start date
Aug 10, 2024 (estimated)
Primary completion
Aug 9, 2027 (estimated)
Completion
Aug 9, 2027 (estimated)
Last update
Jul 31, 2024

Study contacts

Liwei Wang, Doctorate
Contact
lwwang2013@163.com
+86 16621086648
Liwei Wang
Contact
lwwang2013@163.com
+86 16621086648
Liwei Wang, Doctorate
principal investigator · RenJi Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Surufatinib · Serplulimab

Start the discussion